Next-Generation Vergence Recovery Convalescence Platform

A futuristic, AI-driven, and blockchain-enabled dynamic vergence testing platform for personalized, remote, and secure diagnosis and treatment of vergence dysfunction, revolutionizing the field of ophthalmology and traumatic brain injury care.

The original patent disclosed a noninvasive, clinical, objective testing of vergence dysfunction for diagnosis and recovery. However, it lacked the power of AI, machine learning, and blockchain technology to optimize and secure the testing process. The new inventive concept addresses these limitations by introducing a neural network-based prediction module, real-time adaptation of testing protocols, and secure data storage and sharing.

The next-generation platform consists of a wearable, augmented reality-based dynamic vergence testing module, a neural network-based prediction module, and a blockchain-enabled data storage and sharing system. The platform utilizes machine learning algorithms to optimize vergence recovery outcomes in subjects with mild traumatic brain injury (mTBI). It also integrates dynamic vergence testing with functional magnetic resonance imaging (fMRI) to provide a comprehensive understanding of neural correlates of vergence recovery. Additionally, the platform uses dynamic vergence testing to predict the likelihood of long-term cognitive impairment in subjects with mTBI.

The new claims introduce the use of AI, machine learning, and blockchain technology to optimize and secure the dynamic vergence testing process, which is a significant departure from the original patent. The neural network-based prediction module, real-time adaptation of testing protocols, and secure data storage and sharing system are novel and non-obvious features that revolutionize the field of ophthalmology and traumatic brain injury care.

Alternative embodiments of the inventive concept could include the use of other types of AI algorithms, such as deep learning or natural language processing, to optimize vergence recovery outcomes. Other variations could include the integration of dynamic vergence testing with other medical imaging modalities, such as electroencephalography (EEG) or magnetoencephalography (MEG).

The next-generation vergence recovery convalescence platform has significant commercial potential in the fields of ophthalmology, traumatic brain injury care, and personalized medicine. The platform could be marketed to hospitals, clinics, and research institutions, and could potentially disrupt the existing market for vergence testing and treatment.